Multi-Agent Based Automation of Lab Result Delivery and Explanation

This workflow automates the high-volume, repetitive burden of manually reviewing and communicating lab results. It eliminates the operational bottleneck of clinicians sifting through normal results and drafting explanations, redirecting their time to abnormal cases. Savings come from a 60-70% reduction in manual communication tasks, faster patient notification, and mitigated risk from missed urgent findings. The architecture integrates directly with the LIS/EHR via HL7 v2 or FHIR, requiring robust data validation and fallback logic for parsing failures.

Implementation deploys agents using a framework like LangGraph for state management, with the Classification Agent applying reference ranges and clinical logic. The Explanation Agent uses a medically fine-tuned LLM with strict guardrails. Controls include mandatory human review for all abnormal results before patient delivery, configurable escalation thresholds, and full audit trails in the EHR. Observability tracks delivery status, explanation quality, and clinician response times, ensuring the system augments rather than replaces clinical judgment.

The workflow begins when a new lab result arrives via HL7v2 or FHIR from the LIS. An Orchestrator Agent ingests the payload, extracts the patient and test data, and triggers a Classification Agent. This agent compares values against reference ranges and clinical rules to assign a severity tier: normal, abnormal-non-urgent, or abnormal-urgent. This initial classification determines the entire downstream routing path, eliminating manual sorting and prioritizing clinician attention.

For normal results, an Explanation Agent generates a patient-friendly summary delivered via portal or SMS. Abnormal, non-urgent findings are routed to a designated clinician inbox within the EHR for review and sign-off before release. Critical results immediately trigger a Critical Alert Agent to page the on-call clinician and log the action. All paths feed into a centralized audit log for compliance. The system integrates with EHRs like Epic or Cerner, uses a rules engine for tiering logic, and includes mandatory human-in-the-loop gates for all abnormal results to ensure safety and governance.

The initial phase focuses on secure, high-fidelity data ingestion. We implement a dedicated integration agent that consumes HL7 v2 messages from the LIS, normalizes results against dynamic reference ranges, and writes them to a staging database. This agent handles message queuing, retry logic for failed transmissions, and logs all transactions for auditability. The core deliverable is a reliable, observable data pipeline that serves as the single source of truth for downstream automation, eliminating manual data entry and transfer errors.

Phase two introduces the intelligence layer. A classification agent applies configurable rules to flag results as normal, abnormal, or critical. An urgency scoring agent then evaluates abnormal findings against patient history and clinical protocols. Non-critical results are passed to a patient explanation agent, which generates lay-friendly summaries. Critical findings are immediately routed to a clinician alert agent, which prioritizes the inbox or triggers a pager notification based on on-call schedules. This phase directly reduces the cognitive load on staff by filtering out routine notifications.

The governance model must enforce strict oversight on result classification and patient communication. This is achieved by embedding approval gates for abnormal findings, maintaining immutable audit logs of all agent decisions, and integrating with clinical decision support (CDS) rules engines. The architecture connects directly to the lab information system (LIS) via HL7 v2 or FHIR, ensuring data integrity from ingestion through to the EHR. This control layer prevents alert fatigue by filtering noise and ensures only validated, context-aware explanations are delivered to patients via secure portals.

Phased rollout begins with a shadow mode, where the system processes results in parallel with existing workflows without taking action, allowing for validation of classification accuracy and explanation quality. The first live phase targets low-risk, normal results for non-critical panels, with all outputs monitored via a clinical dashboard. Subsequent phases incrementally introduce automation for abnormal flagging and routing, always preserving clinician veto power and immediate system suspension triggers. This measured approach de-risks implementation, builds stakeholder trust, and ties each phase to measurable reductions in manual processing time and patient inquiry call volume.